Q-Line Biotech Limited operates in the In-Vitro Diagnostics (IVD) industry and manufactures as well as trades diagnostic reagents, kits, instruments, consumables, and pathology equipment. The company earns revenue through sales of biochemistry reagents, rapid test kits, ELISA kits, molecular diagnostics products, and diagnostic instruments. These products are widely used in hospitals, pathology laboratories, diagnostic centres, ICUs, and healthcare institutions for disease detection, monitoring, and preventive healthcare solutions.

The Company is led by Promoter, i.e.,Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal

The Revenues from operations for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 23,650.25 Lakh, ₹ 32,258.42 Lakh, ₹ 20,644.81 Lakh, and ₹ 18,481.15 Lakh, The EBITDA for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 6,422.98 Lakh, ₹ 7,132.12 Lakh, ₹ 3,762.50 Lakh, and ₹ 3,297.72 Lakh, The Profit after Tax for the Period ended on Dec 31 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 3,869.39 Lakh, ₹ 2,813.09 Lakh, ₹ 3,444.47 Lakh, and ₹ 3,209.71 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue  EPS of ₹ 28.63 and post-issue EPS of ₹ 12.06 for FY25. The pre-issue P/E ratio is 11.98x,while the post-issue P/E ratio is 28.44x against the Industry P/E ratio is NAx The company's ROE for FY25 is 23.74% and RoNW is 23.74% The Annualised EPS is ₹ 22.12x and P/E is ₹ 15.51x, These metrics suggest that the IPO is Fairly priced.

 
The Grey Market Premium (GMP) of Q-Line Biotech showing listing gains of 14.90%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Apply to the Q-Line Biotech Limited, IPO for Listing gain or Long Term Purposes.